Infinity Pharmaceuticals Inc
OTC:INFIQ

Watchlist Manager
Infinity Pharmaceuticals Inc Logo
Infinity Pharmaceuticals Inc
OTC:INFIQ
Watchlist
Price: 0.0001 USD Market Closed
Market Cap: 91 USD
Have any thoughts about
Infinity Pharmaceuticals Inc?
Write Note

Intrinsic Value

INFIQ's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one INFIQ stock under the Base Case scenario is 29.044 USD. Compared to the current market price of 0.0001 USD, Infinity Pharmaceuticals Inc is Undervalued by 100%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

INFIQ Intrinsic Value
29.044 USD
Undervaluation 100%
Intrinsic Value
Price
Worst Case
Base Case
Best Case
How do you feel about INFIQ?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Infinity Pharmaceuticals Inc

Provide an overview of the primary business activities
of Infinity Pharmaceuticals Inc.

What unique competitive advantages
does Infinity Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does Infinity Pharmaceuticals Inc face in the near future?

Summarize the latest earnings call
of Infinity Pharmaceuticals Inc.

Show all valuation multiples
for Infinity Pharmaceuticals Inc.

Provide P/S
for Infinity Pharmaceuticals Inc.

Provide P/E
for Infinity Pharmaceuticals Inc.

Provide P/OCF
for Infinity Pharmaceuticals Inc.

Provide P/FCFE
for Infinity Pharmaceuticals Inc.

Provide P/B
for Infinity Pharmaceuticals Inc.

Provide EV/S
for Infinity Pharmaceuticals Inc.

Provide EV/GP
for Infinity Pharmaceuticals Inc.

Provide EV/EBITDA
for Infinity Pharmaceuticals Inc.

Provide EV/EBIT
for Infinity Pharmaceuticals Inc.

Provide EV/OCF
for Infinity Pharmaceuticals Inc.

Provide EV/FCFF
for Infinity Pharmaceuticals Inc.

Provide EV/IC
for Infinity Pharmaceuticals Inc.

What are the Revenue projections
for Infinity Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for Infinity Pharmaceuticals Inc?

What are the Net Income projections
for Infinity Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for Infinity Pharmaceuticals Inc?

What are the EPS projections
for Infinity Pharmaceuticals Inc?

How accurate were the past EPS estimates
for Infinity Pharmaceuticals Inc?

What are the EBIT projections
for Infinity Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for Infinity Pharmaceuticals Inc?

Compare the revenue forecasts
for Infinity Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Infinity Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Infinity Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Infinity Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Infinity Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Infinity Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of Infinity Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Infinity Pharmaceuticals Inc.

Provide ROE
for Infinity Pharmaceuticals Inc.

Provide ROA
for Infinity Pharmaceuticals Inc.

Provide ROIC
for Infinity Pharmaceuticals Inc.

Provide ROCE
for Infinity Pharmaceuticals Inc.

Provide Gross Margin
for Infinity Pharmaceuticals Inc.

Provide Operating Margin
for Infinity Pharmaceuticals Inc.

Provide Net Margin
for Infinity Pharmaceuticals Inc.

Provide FCF Margin
for Infinity Pharmaceuticals Inc.

Show all solvency ratios
for Infinity Pharmaceuticals Inc.

Provide D/E Ratio
for Infinity Pharmaceuticals Inc.

Provide D/A Ratio
for Infinity Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for Infinity Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Infinity Pharmaceuticals Inc.

Provide Quick Ratio
for Infinity Pharmaceuticals Inc.

Provide Current Ratio
for Infinity Pharmaceuticals Inc.

Provide Cash Ratio
for Infinity Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Infinity Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Infinity Pharmaceuticals Inc?

What is the current Free Cash Flow
of Infinity Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Infinity Pharmaceuticals Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Infinity Pharmaceuticals Inc

Current Assets 19.9m
Cash & Short-Term Investments 17.7m
Other Current Assets 2.2m
Non-Current Assets 1.3m
PP&E 1.1m
Other Non-Current Assets 200k
Current Liabilities 12.1m
Accounts Payable 1.5m
Accrued Liabilities 10.6m
Non-Current Liabilities 46.5m
Other Non-Current Liabilities 46.5m
Efficiency

Earnings Waterfall
Infinity Pharmaceuticals Inc

Revenue
2.5m USD
Cost of Revenue
-1.5m USD
Gross Profit
1m USD
Operating Expenses
-43m USD
Operating Income
-42m USD
Other Expenses
1.1m USD
Net Income
-40.9m USD

Free Cash Flow Analysis
Infinity Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

INFIQ Profitability Score
Profitability Due Diligence

Infinity Pharmaceuticals Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

Exceptional ROE
Positive Gross Profit
ROE is Increasing
Exceptional 3-Years Revenue Growth
36/100
Profitability
Score

Infinity Pharmaceuticals Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

INFIQ Solvency Score
Solvency Due Diligence

Infinity Pharmaceuticals Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
44/100
Solvency
Score

Infinity Pharmaceuticals Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

INFIQ Price Targets Summary
Infinity Pharmaceuticals Inc

There are no price targets for INFIQ.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for INFIQ?

Click here to dive deeper.

Dividends

Infinity Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for INFIQ is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Infinity Pharmaceuticals Inc Logo
Infinity Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

91 USD

Dividend Yield

0%

Description

Infinity Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 33 full-time employees. The company went IPO on 2000-07-27. The firm is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase 1/1b clinical study.

Contact

MASSACHUSETTS
Cambridge
1100 Massachusetts Ave Ste 4
+16174531000.0
www.infi.com

IPO

2000-07-27

Employees

33

Officers

See Also

Discover More